Business Context and Reporting Period
Company: pSivida Limited (Note: Request metadata listed "Eyepoint, Inc.", but the filing text identifies the registrant as pSivida Limited).
Filing Type: Form 20-F (Annual Report).
Reporting Period: Fiscal year ended June 30, 2006.
Business Overview: pSivida is a global bio-nanotech company focused on developing drug delivery products using three proprietary technologies: Durasert (sustained-release implants), BioSilicon (nanostructured silicon for oncology and diagnostics), and CODRUG (simultaneous release of multiple drugs). The company operates in ophthalmology and oncology sectors. Key products include Vitrasert and Retisert (licensed to Bausch & Lomb) and Medidur (in Phase III trials with Alimera Sciences). The company acquired Control Delivery Systems, Inc. (CDS) on December 30, 2005, significantly expanding its U.S. presence and product pipeline.
Key Financial Metrics (A-IFRS)
| Metric | Year Ended June 30, 2006 | Year Ended June 30, 2005 |
|---|---|---|
| Revenue | A$1,393,000 | A$161,666 |
| Net Loss | (A$28,166,129) | (A$16,793,836) |
| Loss Per Share (Basic & Diluted) | (A$0.09) | (A$0.08) |
| Total Assets | A$235,486,077 | A$91,866,102 |
| Net Assets (Equity) | A$175,032,585 | A$79,695,747 |
| Long-Term Debt | A$3,940,092 | - |
| Cash and Cash Equivalents | A$15,446,552 | A$12,892,061 |
| Net Cash Used in Operating Activities | (A$21,735,693) | (A$12,304,598) |
Note: Financial statements are prepared in Australian Dollars (A$) under A-IFRS. A reconciliation to U.S. GAAP is provided in the filing, showing a U.S. GAAP net loss of A$63.5 million for 2006 due to different accounting treatments for intangibles and derivatives.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 762% to A$1.4 million, driven by the inclusion of CDS operations (royalties from Retisert/Vitrasert and collaborative R&D revenue) post-acquisition.
- Increased Losses: Net loss widened by 68% to A$28.2 million. This was primarily due to:
- Amortization of intangible assets acquired in the CDS merger (approx. A$3.2 million).
- Increased R&D expenses (up 115% to A$17.9 million) for Medidur Phase III trials and BrachySil Phase IIb trials.
- Higher SG&A costs (up 83%) related to U.S. regulatory compliance and share-based payments.
- Balance Sheet Expansion: Total assets more than doubled to A$235.5 million, largely due to the recognition of goodwill (A$53.2 million) and intangible assets (A$162.1 million) from the CDS acquisition.
- Debt Incurrence: The company incurred significant debt in 2006, issuing a US$15 million convertible note in late 2005 and a US$6.5 million note in September 2006. Long-term debt was zero in 2005.
Guidance, Outlook, Risks, and Contingencies
Outlook and Guidance:
- The company expects to continue incurring net losses through at least 2010.
- Management anticipates requiring substantial additional capital to fund operations and product development.
- Revenue is expected to remain low in the near term as Retisert royalties are partially retained by Bausch & Lomb under an advance royalty agreement, and Vitrasert sales continue to decline due to improved AIDS treatments.
Material Risks:
- Liquidity and Going Concern: The auditor has raised substantial doubt about the company's ability to continue as a going concern. The company has a net current liability position and recurring operating losses. It must maintain a minimum cash balance (reduced to US$1.5 million temporarily) to avoid default on its convertible notes.
- Debt Covenants: Failure to meet cash balance requirements or registration deadlines for convertible notes could trigger an event of default, allowing noteholders to demand immediate repayment of the full principal (approx. US$18.5 million outstanding).
- Regulatory Approval: Commercial success depends on FDA approval for Medidur (DME) and BrachySil (liver/pancreatic cancer). Delays or failures in clinical trials would severely impact future revenue.
- Collaboration Dependence: The company relies on partners (Bausch & Lomb, Alimera Sciences) for commercialization. Termination of these agreements or failure of partners to market products effectively poses a significant risk.
Unusual Items:
- Derivative Gains: A non-cash gain of A$3.4 million was recorded due to the revaluation of embedded derivatives in the convertible notes.
- Foreign Exchange: A gain of A$0.7 million resulted from the strengthening of the U.S. dollar and Pound Sterling against the Australian dollar.
Key Facts for Investor Verification
- Cash Runway: Verify current cash balances against the US$1.5 million minimum covenant requirement and the burn rate (approx. A$7.4 million used in operating activities in the quarter ended June 30, 2006).
- Convertible Note Terms: Review the specific redemption triggers and registration deadlines for the US$15 million and US$6.5 million notes to assess default risk.
- Retisert Royalty Structure: Confirm the timeline for when Bausch & Lomb will stop retaining 100% of Retisert royalties (after US$4.75 million of royalties are paid to them).
- Medidur Trial Status: Monitor the progress and results of the Phase III clinical trials for Medidur, as this is the primary near-term revenue catalyst.
- Going Concern Status: Assess the likelihood of securing additional equity or debt financing given the current market conditions and the company's dilution history.